Sat, Oct 25, 2014, 7:18 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Retractable Technologies, Inc. Message Board

repo_105 10 posts  |  Last Activity: Oct 23, 2014 11:23 PM Member since: Apr 5, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • IMHO,HHS should make sure that most Americans get the flu shot this year, to make sure that people don't panic when they come down with symptoms of fever and fatigue, and rush to the emergency rooms due to unfounded fears.

  • Back in 2005 there was an article entitled "Stick It To'em " by Patricia B. Gray that quoted Shaw never wanted the money. (Every investor should google this article and read it) Here is the quote:
    "Last year Retractable Technologies' revenue for the first nine months was $16 million, with a net profit of $55 million, reflecting the one-time gain from the settlements. Retractable lost money on operations for the period. Becton Dickinson posted 2004 revenues of nearly $5 billion, with a net profit of $467 million--down 14% from 2003, in part because of its settlement with Shaw. "I never wanted the money," Shaw says. "I just want to get into the hospitals. Doctors and nurses are dying."

    IMHO, RVP has great products but lousy management. Shaw should keep his word and start distributing it to his minority shareholders.

  • IMHO,the Ebola virus is a wakeup call for every hospital and clinic to provide safety syringes to their healthcare workers.
    The Needle Safety and Prevention Act was passed back in 2000, and unfortunately it hasn't been enforced over the past 14 years. It's a joke what hospitals consider what a safety needle actually is. RVPs victory verdict against BDX is the cake, but RVP'S safety syringe products are the icing.
    The governments of all countries better wake up and start providing safety products and procedures for all their healthcare workers.

  • Reply to

    New Patent Applications

    by tesiman Oct 8, 2014 3:36 PM
    repo_105 repo_105 Oct 8, 2014 11:22 PM Flag

    RVPs Easypoint needle looks the most promising and could be a game changer. From the Fly On The Wall Website: June 24th.
    15:37 EDT RVP Retractable Technologies gets FDA 510k clearance for Easypoint Needle
    The Easypoint Needle from Retractable Technologies was determined to be "Substantially Equivalent" by the FDA on June 17, according to a 510(k) premarket notification posted to the regulator's website. Reference Link :

  • "Vincent A. Forlenza - Chairman, Chief Executive Officer and President
    So we're not a believer in scale for scale's sake. Our strategy is really focused on creating complete solutions for the customer and driving value that way. We think that, that aligns much more with the basic customer needs and how buying processes are evolving. So we really think strategically around each one of these business units and how they can build out solutions. And if you look at how we might work across business units to create more complete solutions, it's a second element of our strategy that we are developing. All of that lines up with -- more with our plug-in M&A strategy. And so that's really the core of what we're trying to do. And certainly, there are people who are playing this out differently in terms of just more and more breadth, but that's not what we're attempting."

  • BD Stuck With $114M Antitrust Verdict After New Trial Denied

    Share us on:     By Jeff Sistrunk
    Law360, Los Angeles (September 30, 2014, 10:42 PM ET) -- A Texas federal judge on Tuesday rejected Becton Dickinson & Co.'s bid to ax a $113.5 million damages verdict in favor of Retractable Technologies Inc. and send the syringe market monopolization case back to a jury for a new trial, ruling that evidence presented during trial supported the jury's findings.

    U.S. District Judge Leonard Davis denied BD's renewed motion for judgment as a matter of law, new trial or remittitur.

    Score one for the little guy................................................

  • Full Fed. Circ. Won't Eye 'Mandate Rule' In Becton IP Case

    Share us on:     By Ryan Davis
    Law360, New York (September 19, 2014, 8:41 PM ET) --" The full Federal Circuit decided Friday not to review the so-called mandate rule requiring lower courts to strictly comply with appeals court decisions, rejecting Becton Dickinson and Co.'s argument that the rule was misapplied when the court refused to reduce a $5 million patent verdict against it.
    Becton was seeking en banc review of a July panel decision that it must pay all of the $5 million award to Retractable Technologies Inc., even though the finding that it infringed was partly reversed by the Federal Circuit three years ago."

    This finally clears up the patent infringement case, and will allow RVP to keep the original $5 million awarded by Judge Davis to RVP .

    IMHO, This event will now free up Judge Davis to make a judgement on the anti-trust case.. It should be coming shortly.

  • Didn't Judge Davis say back in January:"Court addressed the parties and will take under advisement and get a ruling as quickly as it can."

    Good thing I didn't hold my breadth......

  • Reply to

    SEEKING ALPHA article reason for todays move

    by repo_105 Jul 29, 2014 8:26 PM
    repo_105 repo_105 Jul 29, 2014 8:30 PM Flag

    rest of article: RVP

  • Retractable Technologies (RVP) - long - Chris DeMuth Jr.
    •Last year, jury found that BDX tried to monopolize and made false claims.
    •RVP vs. BDX litigation will probably be resolved in 2-4 weeks.
    •Judge will probably nix BDX's "judgment as a matter of law" (JMOL) motion.
    •BDX recorded a charge of $340.5 mil, treble the jury awarded damages.
    •RVP is worth about $12.44 per share on the basis of the litigation.
    •The ultimate judgment could equal almost $22 per RVP share.
    •Odds of $12 are 50%. Odds of $20 are 0%; RVP

3.57-0.04(-1.11%)Oct 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.